How should anticoagulation be initiated in a patient with non‑valvular atrial fibrillation?

How to Start Anticoagulation in Non-Valvular Atrial Fibrillation

Begin by calculating the CHA₂DS₂-VASc score, then start oral anticoagulation immediately if the score is ≥2 in men or ≥3 in women, using a direct oral anticoagulant (DOAC) as first-line therapy unless contraindicated. 1

Step 1: Risk Stratification Using CHA₂DS₂-VASc Score

Calculate the CHA₂DS₂-VASc score to determine stroke risk 1:

• Congestive heart failure: 1 point
• Hypertension: 1 point
• Age ≥75 years: 2 points
• Diabetes mellitus: 1 point
• Prior Stroke/TIA/thromboembolism: 2 points
• Vascular disease: 1 point
• Age 65-74 years: 1 point
• Sex category (female): 1 point

Step 2: Decision to Anticoagulate Based on Score

Score ≥2 (men) or ≥3 (women): Start oral anticoagulation immediately 1

Score = 1 (men) or 2 (women): Consider oral anticoagulation or aspirin based on bleeding risk and patient preference 1. The 2024 ESC guidelines now recommend considering anticoagulation at this threshold 2.

Score = 0 (men) or 1 (women): Omit antithrombotic therapy 1

Step 3: Select the Anticoagulant Agent

First-line options are DOACs 1:

• Apixaban 5 mg twice daily (or 2.5 mg twice daily if ≥2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL)
• Dabigatran 150 mg twice daily (or 110 mg twice daily if age ≥80 or high bleeding risk)
• Rivaroxaban 20 mg once daily with evening meal (15 mg if CrCl 30-49 mL/min)
• Edoxaban 60 mg once daily (30 mg if CrCl 15-50 mL/min, weight ≤60 kg, or on certain P-glycoprotein inhibitors)

Warfarin (target INR 2.0-3.0) is reserved for 1:

• End-stage chronic kidney disease (CrCl <15 mL/min) or hemodialysis
• Mechanical heart valves (contraindication to DOACs)
• Patients unable to maintain therapeutic INR who cannot afford DOACs

Critical Contraindications and Warnings

DOACs are NOT recommended 1:

• End-stage CKD or dialysis (dabigatran and rivaroxaban specifically contraindicated due to lack of safety data)
• Mechanical heart valves (dabigatran showed increased harm in the RE-ALIGN trial)

Step 4: Initiation Protocol

For Stable Outpatients (No Recent Stroke)

Start DOAC immediately at standard or dose-adjusted regimen based on renal function, age, and weight. No bridging with heparin is needed 1.

If starting warfarin:

• Begin at 5 mg daily (lower dose 2.5 mg if age >75, low body weight, or high bleeding risk)
• Check INR weekly until stable in therapeutic range (2.0-3.0)
• Once stable, check INR monthly 1

For Patients Requiring Cardioversion

AF duration ≥48 hours or unknown duration 3:

• Start anticoagulation (warfarin INR 2.0-3.0, or DOAC) for at least 3 weeks before cardioversion
• Continue for at least 4 weeks after cardioversion
• Long-term anticoagulation decision based on CHA₂DS₂-VASc score, not cardioversion success

AF duration <48 hours with CHA₂DS₂-VASc ≥2 (men) or ≥3 (women) 3:

• Administer heparin, factor Xa inhibitor, or direct thrombin inhibitor before cardioversion
• Follow with long-term anticoagulation

Hemodynamically unstable requiring immediate cardioversion 3:

• Cardioverse immediately without delay
• Start anticoagulation as soon as possible
• Continue for at least 4 weeks post-cardioversion

Alternative TEE-Guided Approach

If anticoagulation for 3 weeks is not feasible, perform transesophageal echocardiography 3:

• If no left atrial thrombus: proceed with cardioversion after achieving therapeutic anticoagulation
• Continue anticoagulation for at least 4 weeks post-cardioversion

Step 5: Special Populations

Chronic Kidney Disease

• CrCl >50 mL/min: Standard DOAC dosing
• CrCl 30-50 mL/min: Reduced DOAC doses (apixaban 5→2.5 mg BID if meets criteria, rivaroxaban 20→15 mg daily, edoxaban 60→30 mg daily)
• CrCl 15-30 mL/min: Apixaban 2.5 mg BID may be considered, but limited data 1
• CrCl <15 mL/min or dialysis: Warfarin only (INR 2.0-3.0) 1

Hypertrophic Cardiomyopathy or Cardiac Amyloidosis

Start anticoagulation regardless of CHA₂DS₂-VASc score 2

Post-Acute Ischemic Stroke

This is a complex scenario where timing matters critically 4, 5:

• Do NOT start within 48-72 hours due to hemorrhagic transformation risk
• Small infarcts: Consider starting Day 2-4 6
• Moderate infarcts: Start Day 4-7 6
• Large infarcts: Delay until Day 7-14 6
• Assess infarct size, presence of hemorrhage, and bleeding risk factors before initiating

Common Pitfalls to Avoid

1. Underdosing DOACs: Do not reduce DOAC doses unless specific criteria are met (renal function, age, weight). Inappropriate dose reduction increases stroke risk without reducing bleeding 2.

2. Using DOACs in dialysis patients: Dabigatran and rivaroxaban lack safety data in end-stage renal disease. Use warfarin instead 1.

3. Forgetting to check renal function: Always calculate creatinine clearance before DOAC initiation and recheck periodically, especially in elderly patients 1.

4. Starting anticoagulation too early post-stroke: Parenteral anticoagulation within 48 hours increases hemorrhagic transformation risk 4, 5.

5. Switching stable elderly patients from warfarin to DOACs: The FRAIL-AF trial showed increased bleeding with switching. If elderly patients are stable on warfarin with good INR control, consider maintaining warfarin 2, 7.

6. Adding antiplatelet therapy: Do not add aspirin or other antiplatelets to anticoagulation for stroke prevention—this only increases bleeding risk without additional benefit 2.

Monitoring and Follow-Up

For DOACs:

• Recheck renal function at 3-6 months, then annually (more frequently if CrCl <60 mL/min)
• Assess adherence and bleeding events at each visit
• Reassess CHA₂DS₂-VASc score periodically 1

For Warfarin:

• INR weekly during initiation
• INR monthly once stable in range (2.0-3.0) 1